// App-Quantinova.ai

EP1276 : EXCELLENT COMPARABLE OUTCOMES OF HAPLO-HSCT IN HIGH RISK MYELOID MALIGNANCIES USING MYELOABLATIVE OR REDUCED INTENSITY CONDITIONING WITH LOW RISK OF CGVHD IN RECIPIENTS OF PERIPHERAL BLOOD STEM CELL

Researchers

Presenter

  • Daniele Avenoso

Principal Investigators

  • Riad El Fakih

  • Pramila Krishnamurthy

  • Walid Rasheed

  • Varun Mehra

  • Syed Ahmed

  • Hugues De Lavallade

  • Marwan Shaheen

  • Austin Kulasekararaj

  • Mohmoud Aljurf

  • Shreyans Gandhi

  • Majed Altareb

  • Antonio Pagliuca

  • Francesco Dazzi

  • Michelle Kenion

  • Sarah Ware

  • Ye Ting Leung

  • Victoria Potter

Medical Centers

  • King Faisal Specialist Hospital and Research Centre,Riyad,United Kingdom

  • King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia

  • Haematological Medicine, Kings College Hospital, London, United Kingdom

Locations

  • United Kingdom

  • Saudi Arabia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • Cluster of Differentiation 34

  • Granulocyte colony-stimulating factor

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • fludarabine tablet

  • Tacrolimus

  • Busulfex

  • Thiotepa

  • Fludara injection

  • Filgrastim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved